home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

297 rows where filing_period = "second_quarter", filing_year = 2022 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, income_amount, is_termination, received_date (date)

issue_code 1

  • PHA · 297 ✖

filing_year 1

  • 2022 · 297 ✖

filing_period 1

  • second_quarter · 297 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2813458 STONINGTON GLOBAL ecea9005-868b-4412-9304-8334243b5138 Q2 STONINGTON GLOBAL 401105189 SORRENTO THERAPEUTICS, INC. 2022 second_quarter PHA Regulatory approvals and funding for pharmaceutical products and devices Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 150000   0 0 2022-06-20T16:50:45-04:00
2814122 RED+BLUE STRATEGIES f66462b4-f57f-468a-8441-8ef951deb2eb Q2 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2022 second_quarter PHA S. 1388 - The Prescription Drug Pricing for the People Act - Support for additional transparency across the prescription drug supply chain. S. 4293 - The Pharmacy Benefit Manager Act of 2022 - Issues related to how PBMs work. S. 2938 - The Bipartisan Safer Communities Act of 2022 - Support for legislation and the inclusion of a one year delay of the Trump era Medicare rebate rule. S. 3700 - The INSULIN Act - Issues related to making insulin affordable for all Americans. Issues and legislative vehicles related to capping the price of Insulin. Regulations focused on quality measures used in contracting relationships between pharmacy benefit managers and pharmacies (known as DIR). H.R. 5376 - The Build Back Better Act - Support of full repeal of the Trump Administration's Rebate Rule. PL 117-2 - The American Rescue Plan Act - Implementation of policies related to increasing access to health care coverage, including access to prescription drugs, for Americans with both public and private insurance. HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2022-07-02T15:46:48-04:00
2814172 RED+BLUE STRATEGIES 676b3b06-dc3e-4649-aaf5-a25bb1476458 Q2 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2022 second_quarter PHA S. 3991 - American Made Pharmaceuticals Act - Support for policies that increase the ability for medications across the spectrum to be developed, manufactured and distributed in the US. S. 164 - Biosimilars Education Act of 2021 - A bill to raise awareness of the efficacy and promise of biosimilars in the American health care system. Issues and policies that incent companies to increase their US footprint and adopt Made in America business practices. Policies to help grow the biosimilars marketplace in the United States. Policies focused on improving cancer care through access to affordable treatments. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-04T13:37:15-04:00
2814452 INDEPENDENT PHARMACY COOPERATIVE 40fd2191-aab8-4c1a-b1f4-a376abd6b91e Q2 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2022 second_quarter PHA IPC supports The Pharmacy Benefit Manager Transparency Act of 2022 IPC supports S. 1909/H.R. 3554, the Pharmacy DIR Reform to Reduce Senior Drug Costs Act. Support regulations/laws that would eliminate pharmacy DIR. Medicare Program; Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs(CMS-4192-P). Support with amendments. IPC supports Pharmacists as Providers under Medicare Part B. IPC supports Pharmacy and Medically Underserved Areas Enhancement Act, H.R. 2759/S. 1362 IPC supports Pharmacists as Immunizers IPC supports 340B Program and contract pharmacies IPC supports Federal Retail Pharmacy COVID-19 Vaccination Program expansion. IPC supports MCO Medicaid reform and elimination of spread pricing IPC supports FTC investigation into vertical PBM arrangements Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE,White House Office   30000 0 0 2022-07-05T13:49:27-04:00
2814491 FROST BROWN TODD LLC 9d2c0b11-4fb8-45e8-8571-e94690365c12 Q2 FROST BROWN TODD LLC 283572 DISPOSERX 2022 second_quarter PHA H.R.7667; Issues concerning at home disposal of excess opioids as an option for pharmacies and patients Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE     0 0 2022-07-05T15:04:03-04:00
2814496 4C COMMUNICATIONS, INC. be13b44f-4321-4a46-b608-a8f1c9055a7d Q2 4C COMMUNICATIONS, INC. 323717 HEALTHCARE LEADERSHIP COUNCIL 2022 second_quarter PHA False Claims Act, COVID-19 Response, Vaccine Execution HOUSE OF REPRESENTATIVES,SENATE     0 0 2022-07-05T15:10:14-04:00
2814647 AMERICAN COLLEGE OF CLINICAL PHARMACY b1599788-aa86-4966-8b2b-21786f53e3fb Q2 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2022 second_quarter PHA Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2022-07-06T05:17:58-04:00
2815111 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 12481478-6c02-4d48-abe2-5abb749ed288 Q2 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2022 second_quarter PHA COVID-19 vaccine & therapeutic production, and pandemic protection Pharmaceutical supply chain and domestic manufacturing, workforce development FDA User Fee Reauthorization and associated language HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2022-07-07T11:05:56-04:00
2815217 ACG ADVOCACY fbb2f11d-4ce2-4f40-9de8-ba6b5e950c8b Q2 ACG ADVOCACY 2057 WALGREEN CO. 2022 second_quarter PHA Drug Pricing Policy Issues. Data privacy and DIR fee reform. Counterfeiting Issues. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2022-07-07T14:28:54-04:00
2815334 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 62bdcd24-6b08-498d-9069-f034d8c4b9d9 Q2 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 35968 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2022 second_quarter PHA Compounding, preparation, packaging and dispensing of radiopharmaceuticals Food & Drug Administration (FDA)   60000 0 0 2022-07-07T17:13:01-04:00
2815593 KOUNTOUPES DENHAM CARR & REID, LLC 2f46634f-6bb8-47df-b1bc-fad0fc85aa2e Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CVS HEALTH 2022 second_quarter PHA General education about the pharmacy benefit manager/pharmacy and insurance industry. Issues related to drug pricing. Issues related to the drug supply chain. Issues related to the implementation of H.R. 1319, The American Rescue Plan, including provisions related to vaccine distribution. Issues related to the Fiscal Year 2022 budget reconciliation process focusing on drug pricing, including H.R. 5376, the Build Back Better Act. Issues related to pharmacy provider status, including H.R. 7213, the Equitable Community Access to Pharmacist Services Act. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2022-07-08T11:49:25-04:00
2815653 KOUNTOUPES DENHAM CARR & REID, LLC 9b7dc5f7-9a93-465c-b7ee-50175462274e Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 GLENMARK PHARMACEUTICALS, INC., USA 2022 second_quarter PHA Issues related to affordability, essential medicine manufacturing and pharmaceuticals. General issues related to the generic drug industry. Issues related to H.R. 2853, the BLOCKING Act of 2021. Issues related to pharmaceutical provisions in H.R. 5376, the Build Back Better Act. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2022-07-08T12:35:09-04:00
2815880 DAVE KOLBE CONSULTING f3514d38-4ef2-457f-81a2-a3c3edb2b840 Q2 DAVE KOLBE CONSULTING 401104329 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2022 second_quarter PHA Reauthorization of the Prescription Drug User Fee Act (PDUFA) - Support for a strong PDUFA reauthorization that ensures Americans will continue to have first access to life-saving biopharmaceutical medicines throughout the length of the reauthorization. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2022-07-09T08:49:38-04:00
2816092 HEALTHSPERIEN fe037c27-1421-42b8-9a7d-b9e25888443c Q2 HEALTHSPERIEN 401103150 EXACT CARE PHARMACY 2022 second_quarter PHA o Advocate for codifying definition for long-term care pharmacy. (S. 1574) o Advocate for inclusion of chronic care pharmacy in CMMI model demonstration programs Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2022-07-10T16:23:46-04:00
2816127 PENN AVENUE PARTNERS b26f5695-3afd-4b97-964e-d9a564ee1032 Q2 PENN AVENUE PARTNERS 400918672 ALKERMES, INC. 2022 second_quarter PHA Regulatory and legislative issues impacting Alkermes. S.3593 - Telehealth Extension and Evaluation Act. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2022-07-10T20:03:15-04:00
2816707 BROWN & FORTUNATO, P.C. cddf56b6-3b90-48e3-b3b1-ffd974da3115 Q2 BROWN & FORTUNATO, P.C. 401104878 PROMPTCARE COMPANIES, INC. 2022 second_quarter PHA Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program and Medicare coverage and payment for non-invasive ventilators. Centers For Medicare and Medicaid Services (CMS) 20000   0 0 2022-07-11T18:23:46-04:00
2817211 TRINITY HEALTH cf119f4e-0451-4017-be85-72e11eb5f707 Q2 TRINITY HEALTH 24910 TRINITY HEALTH 2022 second_quarter PHA HR 7213 To provide pharmacy reimbursement for COVID-19-related and future emergency services HOUSE OF REPRESENTATIVES   200000 0 0 2022-07-12T13:52:54-04:00
2817353 MLJ STRATEGIES fc0f5d4b-6428-41e7-b0c2-5f009724065c Q2 MLJ STRATEGIES 401105126 ANKURA CONSULTING GROUP, LLC ON BEHALF OF ON DEMAND PHARMACEUTICALS 2022 second_quarter PHA Advocating on issues related to pharmaceutical appropriations HOUSE OF REPRESENTATIVES,SENATE     0 0 2022-07-12T15:07:59-04:00
2817359 MLJ STRATEGIES 40de16fa-30d4-4a80-992b-4f05717ffd44 Q2 MLJ STRATEGIES 401105126 ANKURA CONSULTING GROUP, LLC ON BEHALF OF THORNE RESEARCH 2022 second_quarter PHA Advocate on issues related to supplement use in the military HOUSE OF REPRESENTATIVES,SENATE     0 0 2022-07-12T15:10:47-04:00
2817408 AMERICAN PHARMACISTS ASSOCIATION 4116df36-40b4-4c29-9917-e6798ecf7d6f Q2 AMERICAN PHARMACISTS ASSOCIATION 3071 AMERICAN PHARMACISTS ASSOCIATION 2022 second_quarter PHA H.R. 3554/S.1909 The Pharmacy DIR Reform To Reduce Senior Drug Costs Act, to amend title XVIII of the Social Security Act to reform requirements with respect to direct and indirect remuneration under Medicare part D, and for other purposes. H.R. 3662 -- The Patient Access to Urgent-Use Pharmacy Compounding Act of 2021, to amend the Federal Food, Drug, and Cosmetic Act to ensure patients have access to certain urgent-use compounded medications, and for other purposes. H.R. 3682 --To amend title XI of the Social Security Act to provide greater transparency for discounts provided by manufacturers. H.R. 2608 --Ensuring Seniors Access to Local Pharmacies Act of 2021, a bill that establishes several requirements for prescription drug plans under the Medicare prescription drug benefit. H.R. 7213 - To amend title XVIII of the Social Security Act to provide pharmacy reimbursement for COVID-19-related and future emergency services. HOUSE OF REPRESENTATIVES,SENATE   35000 0 0 2022-07-12T15:45:48-04:00
2817568 MCDERMOTT+ LLC 7ce445aa-1cb7-4d52-8c5c-984ff47ccb2c Q2 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2022 second_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program, including the Closing Loopholes for Orphan Drugs Act (H.R. 853). HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2022-07-12T17:03:58-04:00
2817865 BROYDRICK & ASSOCIATES 576e40ee-3bb3-4f12-98d0-e210eff9714c Q2 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2022 second_quarter PHA Funding new drug for PTSD and COVID 19. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2022-07-13T10:20:57-04:00
2817896 HOLLAND & KNIGHT LLP dc7c6776-315c-4fca-8ee1-ad07ded941fb Q2 HOLLAND & KNIGHT LLP 18466 VIATRIS INC 2022 second_quarter PHA Drug shortages, formulary tiering, Ensuring Access to Lower-Cost Medicines for Seniors Act of 2021 (H.R. 2846), biosimilar uptake, Medicare generics penalty, generic drugs issues, supply chain issues, e-labeling provision in the FY2022 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill (H.R. 4356), and Military Construction, Veterans Affairs, and Related Agencies appropriations bill (H.R. 4355), Prescription Drug Pricing Dashboard Act (S. 1773); drug pricing; Build Back Better Act (H.R. 5376); Enhanced Access to Affordable Medicines Act of 2022 (H.R. 6973); Increasing Transparency in Generic Drug Applications Act of 2022 (H.R. 7032); Generic Drug User Fee Amendments. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-13T10:48:43-04:00
2818409 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION f21cd584-80ff-436a-bf3c-eec93b7a10f8 Q2 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2022 second_quarter PHA OTC switch process -- no bill number H.R. 6000 - 21st Century Cures 2.0 S.1435/HR 2873 - Affordable Prescriptions for Patients Act of 2021 H.R.4405 - Small Business FDA User Fee Adjustment Act of 2021 H.R. 7667 - Food and Drug Amendments of 2022 Dietary Supplement Reform -- no bill number Cosmetics Reform -- no bill number S. 4348 - Food and Drug Administration Safety and Landmark Advancements Act of 2022 or the FDASLA Act of 2022 Genus vs. FDA Circuit Court Lobby Activity Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE   160270 0 0 2022-07-13T16:20:50-04:00
2818460 WAXMAN STRATEGIES de8c62dd-c4cb-4dde-a8fb-517d106ef286 Q2 WAXMAN STRATEGIES 401103693 340B HEALTH 2022 second_quarter PHA Issues affecting the 340B drug pricing program; Appropriations for 340B program. HOUSE OF REPRESENTATIVES,SENATE 45000   0 0 2022-07-13T16:40:02-04:00
2818593 WATKINS & EAGER PLLC 700bf9e7-7990-409d-9bef-e8f341f1c15f Q2 WATKINS & EAGER PLLC 401104403 ZYNERBA PHARMACEUTICALS, INC. 2022 second_quarter PHA Providing services on behalf of Zynerba to the pharmaceutical industry - looking for testing sites HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2022-07-13T20:29:39-04:00
2818709 CONNECT 4 STRATEGIES, LLC 37da72f4-cd9c-4d05-945e-38e45f4c6b01 Q2 CONNECT 4 STRATEGIES, LLC 401103720 OREXO US, INC. 2022 second_quarter PHA Legislative and regulatory issues pertaining to Orexo Access to treatment for SUD/OUD/MAT Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-14T10:08:20-04:00
2818754 LUNGREN LOPINA LLC bc10c58c-3d0b-40e2-862f-df02158d7273 Q2 LUNGREN LOPINA LLC 401103314 AMPAC FINE CHEMICALS 2022 second_quarter PHA Fair treatment for US based pharmaceutical ingredients HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2022-07-14T10:47:06-04:00
2818955 PANNONE LOPES DEVEREAUX & O'GARA LLC eb6dffce-f163-4764-aa49-4cadf14c250c Q2 PANNONE LOPES DEVEREAUX & O'GARA LLC 401105501 AMGEN 2022 second_quarter PHA Prescription drug pricing.   9000   0 0 2022-07-14T12:55:29-04:00
2819145 RAY ANDERSON 5fea5eee-7021-417f-8dc5-55fd956d1ed6 Q2 RAY ANDERSON 401105487 340B HEALTH 2022 second_quarter PHA Requesting the Secretary of Health and Human Services and HRSA to enforce a statute ordering drug companies to restore 340B discounts to eligible hospitals Requesting Centers for Medicare and Medicaid Services to restore the Medicare hospital Outpatient Prospective Payment System reimbursement rate Requested Representative Spanberger and Representative Danny K. Davis and members of the Congressional Black Caucus participation in a Congressional Special Order Hour session. Gathered CBC member signatures on a Dear Colleague request to Secretary of HHS Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA) 15000   0 0 2022-07-14T14:18:58-04:00
2819165 PUBLIC CITIZEN f7f4362f-9174-49ad-84b5-97393936c8ff Q2 PUBLIC CITIZEN 32362 PUBLIC CITIZEN 2022 second_quarter PHA HR 4502-(fy2022 Consolidated Appropriations Act), Covid-19 Vaccine manufacturing, delivery and access and related funding, S 3799 Prevent Pandemics Act (R&D Access conditions, Public MCM manufacturing, Discounted drugs for clinical Trials Act, Pharmaceutical Research and Transparency Act, Generic Substitution Non-Interference Act, drug pricing, FDA-PTO coordination, orange book reform, NDAA licensing access and drug pricing conditions, S 3700-Affordable Insulin Now Act, Drug pricing patent licensing executive Action, Compulsory licensing to lower drug prices, HR 4521-COMPETES Act mandatory drug recall authority provision, HR 7667/ S 4348-User fee legislation, advisory committee and recall provisions, NIH Director position, Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   110000 0 0 2022-07-14T14:21:58-04:00
2819246 PARDES BIOSCIENCES, INC. f0f621c3-7532-4264-a92d-e5f40ff50dcd Q2 PARDES BIOSCIENCES, INC. 401106493 PARDES BIOSCIENCES, INC. 2022 second_quarter PHA Covid Oral Anti Virals Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE   120000 0 0 2022-07-14T14:54:50-04:00
2819789 MARSHALL & POPP, LLC c10c8a18-c4ba-4891-839d-a6f0a2cec437 Q2 MARSHALL & POPP, LLC 401105121 AMGEN USA INC. 2022 second_quarter PHA Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-15T00:33:58-04:00
2819795 MARSHALL & POPP, LLC 9af5225f-3314-47dc-8f4b-6e5edb9d6c74 Q2 MARSHALL & POPP, LLC 401105121 BUTTERFLY NETWORK, INC. 2022 second_quarter PHA Issues related to medical device manufacturing / insurance / technology, including S.3799, the PREVENT Pandemics Act. Issues related to FDA regulation of medical devices, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-15T00:38:34-04:00
2819799 MARSHALL & POPP, LLC 6702f07a-360d-4b9a-85ff-00afa5e530c4 Q2 MARSHALL & POPP, LLC 401105121 GENENTECH, INC. 2022 second_quarter PHA Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-15T00:51:16-04:00
2820001 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION b63ccaea-997c-4553-9a66-67110bd9ce2c Q2 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2022 second_quarter PHA S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021; H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021; H.R. 3656, the Vaccine Access Improvement Act of 2021; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; COVID vaccine distribution; Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act; H.R. 4390, the PROTECT 340B Act of 2021; S. 1574 / H.R. 5632, the Long-Term Care Pharmacy Definition Act of 2021; Provider Relief Fund; Implementation of Pubic Law 113-54, the Drug Quality and Security Act; H.R. 6005, the Access to Birth Control Act; H.R. 6000, Cures 2.0 Act; H.R. 6519, Patients Right to Know Their Medication Act of 2022; Draft legislation, Pharmacy Price Transparency Protection Act; H.R. 7559, Prescription Information Modernization Act; Draft legislation, To ensure that private health insurers are able to provide appropriate oversight of entities providing pharmacy benefit manager services Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE,White House Office   460000 0 0 2022-07-15T09:57:02-04:00
2820215 BLUESTONE STRATEGIES, LLC c483bbb7-7867-4fee-97fa-d033e4561263 Q2 BLUESTONE STRATEGIES, LLC 400658980 AMERICA'S HEALTH INSURANCE PLANS (AHIP) 2022 second_quarter PHA HR 3, Lower Drug Costs Now Act; HR 5260, Reduced Cost and Continued Care Act; Specialty Drugs and Prescription Drug Pricing, HR 19. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-15T11:15:53-04:00
2820234 BLUESTONE STRATEGIES, LLC 11b91b56-f183-409c-a151-ef5db0684aac Q2 BLUESTONE STRATEGIES, LLC 400658980 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2022 second_quarter PHA Pharmacy Act; Drug Pricing; Generic Brand Settlement; Generic Dispensing; Generic Biologics; & Specialty Drug Issues. HR 5260 Reduced Cost & Continued Care Act of 2021. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-15T11:21:06-04:00
2820513 KOUNTOUPES DENHAM CARR & REID, LLC 26cd3817-2949-4029-b9d4-3e953f12c310 Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) 2022 second_quarter PHA Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing, and supply chain. Issues related to H.R. 2853, BLOCKING Act of 2021. Issues related to pharmaceutical patents. Issues related to drug pricing. Issues related to FDA provisions in S. 3799, the PREVENT Pandemics Act. Issues related to the Generic Drug User Fee Act (GDUFA) and the Biosimilar User Fee Act (BsUFA) in H.R. 7667, the Food and Drugs Amendments to 2022, and S. 4348, the Food and Drug Administration Safety and Landmark Advancements Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-15T13:01:25-04:00
2820578 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 08120c7c-1b48-4cfc-bbde-7849afabd7a2 Q2 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 401104060 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 2022 second_quarter PHA General education around pharmaceuticals related to Parkinson's disease Increasing drug affordability and accessibility via drug pricing, Medicare Part D redesign and benefits, and streamlining prior authorization processes and step therapy protocols Prescription Drug User Fee Act H.R. 4417, the Capping Drug Costs for Seniors Act H.R. 4479/S. 2609, the Facilitating Innovative Nuclear Diagnostics Act of 2021 S. 2327, the Seniors Prescription Drug Relief Act H.R. 3173/S. 3018, the Improving Seniors Timely Access to Care Act of 2021 H.R. 2163, the Safe Step Act H.R. 5801, the Help Ensure Lower Patient (HELP) Copays Act Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   61153 0 0 2022-07-15T13:25:25-04:00
2820708 NELSON MULLINS RILEY & SCARBOROUGH 3228b725-e8bd-494c-a4e0-e2eb7a2d0833 Q2 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2022 second_quarter PHA 340B Drug Pricing Program, patient co-pay policies HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2022-07-15T14:37:51-04:00
2821155 ASCENSION HEALTH ALLIANCE D/B/A ASCENSION 7fa2c441-fb2c-459c-922f-662cb9edcbbe Q2 ASCENSION HEALTH ALLIANCE D/B/A ASCENSION 401105339 ASCENSION HEALTH ALLIANCE D/B/A ASCENSION 2022 second_quarter PHA 340B Drug Pricing Program; Issues related to 340B contract pharmacies; Financial support for providers for diagnosis and treatment related to COVID-19, including funding for the Provider Relief Fund; coverage of COVID-19 related conditions; S. 168/H.R. 708 - Temporary; Reciprocity to Ensure Access to Treatment (TREAT) Act; S. 346/H.R. 959 - Black Maternal Health Momnibus Act; S. 773/H.R. 3203 - Legislation related to 340B eligibility; S. 368/H.R. 1332 - Telehealth Modernization Act; S. 1512/H.R. 2903 - CONNECT for Health Act; S. 1988 -Protecting Rural Telehealth Access Act; H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act; S.773/H.R. 3203 - A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program; - S.773/H.R. 3203; H.R. 5376 - Build Back Better Act; H.R. 853 - Closing Loopholes for Orphan Drugs Act; H.R. 2471 - Consolidated Appropriations Act (FY 2022 Omnibus); H.R. 7007 - Covid-19 Supplemental Appropriations Act Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   250000 0 0 2022-07-15T17:06:12-04:00
2821552 REPUBLIC CONSULTING, LLC 193466ad-99bc-4677-b6eb-e7b47058f3db Q2 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2022 second_quarter PHA Monitored Health Data Policy. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-16T09:05:36-04:00
2821626 FORBES-TATE 396f1e9f-c53f-4881-a279-eb894395f2de Q2 FORBES-TATE 400976792 CALIFORNIA LIFE SCIENCES ASSOCIATION 2022 second_quarter PHA Issues related to the life sciences industry; Issues related to drug pricing and international reference pricing. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2022-07-16T11:06:38-04:00
2822002 TREMONT STRATEGIES GROUP LLC (F/K/A ADS VENTURES) 5f5e34f5-1b35-453d-9697-cfb31d1d2c45 Q2 TREMONT STRATEGIES GROUP LLC (F/K/A ADS VENTURES) 90250 AMAG PHARMACEUTICAL 2022 second_quarter PHA Pharmaceutical issues; access to women's health pharmaceutical products. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2022-07-16T17:19:38-04:00
2822038 PENN AVENUE PARTNERS 45c61c39-a8c2-4cf4-858f-cca3e1e2cbeb Q2 PENN AVENUE PARTNERS 400918672 UNITEDHEALTH GROUP, INC. 2022 second_quarter PHA Pharmacy benefit related issues. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office 90000   0 0 2022-07-16T18:28:45-04:00
2822104 FORBES-TATE 28192c5a-d3c2-4d06-9abe-944bab1a0337 Q2 FORBES-TATE 400976792 INDEPENDENT PHARMACY COOPERATIVE 2022 second_quarter PHA Issues related to pharmacy regulation, the MAC Transparency Act, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-16T19:44:37-04:00
2822264 MARSHALL & POPP, LLC 7b1ad209-0240-45e8-802f-fac6bde20456 Q2 MARSHALL & POPP, LLC 401105121 PFIZER, INC. 2022 second_quarter PHA Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-17T08:26:01-04:00
2822269 MARSHALL & POPP, LLC fffbf069-66e0-4830-9119-2c95039df101 Q2 MARSHALL & POPP, LLC 401105121 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2022 second_quarter PHA Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S. 2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2022-07-17T08:32:03-04:00
2822273 MARSHALL & POPP, LLC 7ea0bff6-25fe-45b6-9a7d-aecb11b1b3fc Q2 MARSHALL & POPP, LLC 401105121 SANOFI U.S. SERVICES, INC. 2022 second_quarter PHA Issues related to prescription drug value, including H.R.3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R.22/S.2164, the Lower Costs, More Cures Act; H.R.5376, the Build Back Better Act, and budget reconciliation recommendations released by Senate committees pursuant to S.Con.Res. 14. Issues related to vaccine development and distribution. Issues related to supply chains, 340B, and the COVID-19 pandemic. Issues related to insulin, including H.R.6833, Affordable Insulin Now Act. Issues related to FDA regulation of pharmaceuticals, including S.4348, Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-17T08:38:32-04:00
2822551 FORBES-TATE b416d924-cc4d-4cae-9694-5a3931d19d75 Q2 FORBES-TATE 400976792 PHRMA 2022 second_quarter PHA Issues pertaining to prescription drug pricing. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2022-07-17T14:16:53-04:00
2822646 CAPITOL COUNSEL LLC 25e0bdcf-0ec2-43b6-80db-906bb50a7018 Q2 CAPITOL COUNSEL LLC 313715 EMD SERONO, INC. 2022 second_quarter PHA Monitoring and engaging on health policy proposals coming before the House of Representatives and the Administration pertaining to the availability and pricing of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2022-07-17T16:26:28-04:00
2822658 CAPITOL COUNSEL LLC 56c25589-cbd2-4f35-ba36-c041511b644d Q2 CAPITOL COUNSEL LLC 313715 VERTEX PHARMACEUTICALS INCORPORATED 2022 second_quarter PHA Monitoring and advocacy on matters related to the pharmaceutical industry. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2022-07-17T16:42:04-04:00
2822965 CORNERSTONE GOVERNMENT AFFAIRS, INC. 31b95f88-9259-47dd-b366-be75e534816d Q2 CORNERSTONE GOVERNMENT AFFAIRS, INC. 75557 CHILDREN'S NATIONAL MEDICAL CENTER 2022 second_quarter PHA Representation on health-related issues including reimbursement, research, public-health & clinical care Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2022-07-17T22:39:24-04:00
2823610 FLYNN & ASSOCIATES, INC. 9c5efdb3-743c-4364-8d0c-37dbcf8702d9 Q2 FLYNN & ASSOCIATES, INC. 15020 PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION 2022 second_quarter PHA Price controls for prescription drugs. Importation of drugs from other countries. Prescription Drug User Fee Act (reauthorization). HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-18T11:40:39-04:00
2824093 TWENTY-FIRST CENTURY GROUP, INC. 24b28cce-5ab1-40af-9b18-3ddb667ceea4 Q2 TWENTY-FIRST CENTURY GROUP, INC. 38687 CARDINAL HEALTH, INC. 2022 second_quarter PHA Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; COVID-19 pandemic response; and the healthcare supply chain. HOUSE OF REPRESENTATIVES,SENATE 24000   0 0 2022-07-18T12:57:44-04:00
2824172 CARD & ASSOCIATES, LLC 394e059f-29b3-41be-a90c-afcadef72fa1 Q2 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2022 second_quarter PHA Monitoring legislation on drug price transparency and market access issues including legislative proposals related to drug pricing Monitoring federal appropriations for FY 2022 Access to telemedicine HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2022-07-18T13:11:03-04:00
2824310 POLSINELLI PC 161ace94-c756-40ab-af67-723a292d99c0 Q2 POLSINELLI PC 314911 TEVA PHARMACEUTICALS USA, INC. 2022 second_quarter PHA Issues related to pricing, reimbursement, and manufacturing of pharmaceutical products Review of Administration telehealth policies HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2022-07-18T13:34:31-04:00
2824319 AMERICAN VETERINARY MEDICAL ASSOCIATION f42a7c2c-4561-4817-9b66-9ba715c06702 Q2 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2022 second_quarter PHA Review of Food and Drug Administrations Final Guidance for industry #256: Compounding Animal Drugs from Bulk Drug Substances Prescription Mandate legislation Animal Drug User Fee Act/ Animal Generic Drug User Fee Act reauthorization Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 260000   0 0 2022-07-18T13:36:53-04:00
2824418 RICCHETTI INCORPORATED dd391673-662b-40d3-a3d3-9255df8906c0 Q2 RICCHETTI INCORPORATED 62778 EISAI, INC. 2022 second_quarter PHA Issues related to coverage of Alzheimer's drugs and diagnostics under Federal health care programs; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement; Issues related to pharmaceutical industry, generally HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2022-07-18T13:55:23-04:00
2824450 RICCHETTI INCORPORATED e2b113aa-7773-4180-9800-b8a3811ba3c1 Q2 RICCHETTI INCORPORATED 62778 HORIZON THERAPEUTICS USA INC 2022 second_quarter PHA Issues related to pharmaceutical industry, generally Issues related to drug pricing and access, and Medicare and Medicaid reimbursement HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2022-07-18T14:00:28-04:00
2824527 RICCHETTI INCORPORATED 388f4952-ec6e-4fc1-be5d-fd3da4fe9d44 Q2 RICCHETTI INCORPORATED 62778 IPSEN BIOPHARMACEUTICALS, INC. 2022 second_quarter PHA Issues related to pharmaceutical industry, generally Issues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP) HOUSE OF REPRESENTATIVES 20000   0 0 2022-07-18T14:09:37-04:00
2824559 RICCHETTI INCORPORATED b0ffeaa9-e4dc-4860-a099-8aaf83936f10 Q2 RICCHETTI INCORPORATED 62778 NEUROCRINE BIOSCIENCES, INC. 2022 second_quarter PHA Issues related to pharmaceutical industry, generally HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2022-07-18T14:14:23-04:00
2824571 RICCHETTI INCORPORATED ec919991-0677-4c9a-8e89-369fbe12867d Q2 RICCHETTI INCORPORATED 62778 PARDES BIOSCIENCES, INC. 2022 second_quarter PHA Issues related to government involvement in the development of COVID-10 therapies HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2022-07-18T14:16:00-04:00
2824625 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS dd2d3682-a0e3-4555-867c-5a9633c77136 Q2 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2022 second_quarter PHA Communication with Senate to pass insulin affordability legislation. Discussion with White House requesting response to drug contrast shortages. Contact concerning FDA authority to manage drug shortages, regulation of pharmacy compounding, implementation of the Drug Quality and Security Act. Conversation with DEA regulation on Medication-Assisted Treatment and drug shortages. Discussed COVID-19 response recommendations with House and Senate Offices, White House Offices, and HHS and its sub-agencies, and DEA. Contact HHS, House and Senate Offices concerning rule enforcement of the 340B Drug Pricing Program. Met with House and Senate offices to discuss the Protect 340B Act (H.R. 4390) and bills S.773 and H.R. 3203, also related to the 340B program. Discussed role out of Test to Treat Program with HHS and its agencies. Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   528641 0 0 2022-07-18T14:23:24-04:00
2824680 FAEGRE DRINKER BIDDLE & REATH LLP 3579d951-469a-46f1-b516-1f7eacc233e9 Q2 FAEGRE DRINKER BIDDLE & REATH LLP 12631 ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP GLOBAL) 2022 second_quarter PHA Illicit prescription drug sales online; Rogue internet drug sellers; Dangers of counterfeit medicines; Risks of drug importation on patient safety; Domain name system accountability; STOP Act implementation; S. 1843, H.R. 3429 - SHOP SAFE Act. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2022-07-18T14:29:53-04:00
2825473 E3 STRATEGIC CONSULTING GROUP c25d0c6c-afb5-4784-996a-fca12423f1e0 Q2 E3 STRATEGIC CONSULTING GROUP 401104104 HEINZ STRATEGIES LLC (ON BEHALF OF PILMA) 2022 second_quarter PHA Monitoring prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally   20000   0 0 2022-07-18T15:59:05-04:00
2825476 E3 STRATEGIC CONSULTING GROUP 66b41a83-5312-4aec-8557-e9570595a2e4 Q2 E3 STRATEGIC CONSULTING GROUP 401104104 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2022 second_quarter PHA Monitoring prescription drug industry issues relating to domestic construction and maintenance employment and all other issues affecting employment in the industry, generally   20000   0 0 2022-07-18T15:59:45-04:00
2825767 SQUIRE PATTON BOGGS 2837cf26-2af5-44de-bfe8-9d38f6b358ec Q2 SQUIRE PATTON BOGGS 30906 SK HYNIX AMERICA, INC. 2022 second_quarter PHA Monitor proposals and issues related to biopharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 130000   0 0 2022-07-18T16:47:16-04:00
2825792 FAEGRE DRINKER BIDDLE & REATH LLP 2e6731af-8c24-49c2-a17f-69d40304fb7c Q2 FAEGRE DRINKER BIDDLE & REATH LLP 12631 NATIONAL ASSOCIATION OF BOARDS OF PHARMACY 2022 second_quarter PHA Medication safety, pharmacy regulation and licensure, and the opioid epidemic; Prescription drug monitoring programs; COVID-19 response; H.R.2482, S. 2074 - Mainstreaming Addiction Treatment Act; Prescription drug importation; H.R. 6352, S. 3399 - Domain Reform for Unlawful Drug Sellers Act. Drug Enforcement Administration (DEA),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE 50000   0 0 2022-07-18T16:50:46-04:00
2825859 340B HEALTH 3ff639a5-50b7-48a6-899b-634896701271 Q2 340B HEALTH 316434 340B HEALTH 2022 second_quarter PHA The 340B Drug Pricing Program; H.R.4390 - PROTECT 340B Act of 2021; Labor HHS Appropriations FY 2023; HR853 Closing Loopholes for Orphan Drugs Act; S. 2837, the 340B Accountability Act of 2021 Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   298834 0 0 2022-07-18T17:07:22-04:00
2826061 ALB SOLUTIONS 67527880-adc7-4d5f-a24e-eacd8f02d813 Q2 ALB SOLUTIONS 401105973 BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2022 second_quarter PHA Issues related to regulatory and legislative developments regarding biosimilars. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2022-07-18T17:47:40-04:00
2826142 HUMANITY FORWARD 333e8607-ccaf-42a0-8dd2-f1c1426f0757 Q2 HUMANITY FORWARD 401105867 HUMANITY FORWARD 2022 second_quarter PHA Issues and legislation related to reduction of prescription medication for Americans HOUSE OF REPRESENTATIVES,SENATE   350000 0 0 2022-07-18T18:18:08-04:00
2826188 HUMANITY FORWARD 09a64b11-2d75-425e-97af-9505edaebd96 2A HUMANITY FORWARD 401105867 HUMANITY FORWARD 2022 second_quarter PHA Issues and legislation related to reduction of prescription medication for Americans HOUSE OF REPRESENTATIVES,SENATE   263000 0 0 2022-07-18T18:34:43-04:00
2826256 ARENTFOX SCHIFF LLP e4b429b7-65db-4b00-8c72-4517c8c1ddb3 Q2 ARENTFOX SCHIFF LLP 4208 AMERICAN PHARMACY COOPERATIVE, INC. 2022 second_quarter PHA Prescription drug pricing generally S. 4293 (Pharmacy Benefit Manager Transparency Act of 2022), regarding prescription drug pricing HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2022-07-18T18:57:55-04:00
2826335 NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) dd556bd0-0b29-4ae4-a0d0-15bce8d00c8d Q2 NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) 28264 NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) 2022 second_quarter PHA Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. User Fee Agreements. Prescription Drug User Fee Act (PDUFA) Reauthorization. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2022-07-18T19:26:39-04:00
2826500 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) dc00256f-0827-4048-805e-d832bb40b186 Q2 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 401105192 CVS HEALTH 2022 second_quarter PHA Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs. Issues related to the continuation of prescription drug access and testing during COVID crisis. Issues related to Medicare Part D rebates. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-18T20:49:22-04:00
2826538 BROWNSTEIN HYATT FARBER SCHRECK, LLP 6586afdb-6bc8-4bc9-b2ed-d062914ebdf9 Q2 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 WALGREEN CO. 2022 second_quarter PHA Pharmacist provider status Pharmacy benefits on military bases Issues related to COVID-19 relief Issues related to drug pricing H.R.5376 - Build Back Better Act Issues related to Infrastructure Investment and Jobs Act (PL 117-58) implementation HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-18T21:12:13-04:00
2826842 BROWNSTEIN HYATT FARBER SCHRECK, LLP 3c900d28-5164-464b-8233-9d6bf0da670a Q2 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 MEDIVANT HEALTHCARE 2022 second_quarter PHA Issues related to pharmaceutical manufacturing and supply       0 0 2022-07-18T22:29:41-04:00
2826843 BROWNSTEIN HYATT FARBER SCHRECK, LLP c3b5052e-0ed4-49b4-9706-54c80b27046e Q2 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 MEDIVANT HEALTHCARE 2022 second_quarter PHA Issues related to pharmaceutical manufacturing and supply       0 0 2022-07-18T22:29:50-04:00
2826874 THE MATHIS HARPLE GROUP f44663db-4e73-4148-bf8c-69f6de4d5c53 Q2 THE MATHIS HARPLE GROUP 322911 PILMA 2022 second_quarter PHA Price Controls, Intellectual Property Rights HOUSE OF REPRESENTATIVES,SENATE     0 0 2022-07-18T22:36:49-04:00
2826987 THE MATHIS HARPLE GROUP a1b7bc2a-b7fe-4d46-90ec-c7b2597861bb Q2 THE MATHIS HARPLE GROUP 322911 PHRMA 2022 second_quarter PHA Price Controls, Intellectual Property Rights HOUSE OF REPRESENTATIVES,SENATE     0 0 2022-07-18T23:09:31-04:00
2827238 VAN SCOYOC ASSOCIATES b3f19194-4458-422e-883a-5018104da55d Q2 VAN SCOYOC ASSOCIATES 39837 ZEBRA TECHNOLOGIES CORP. 2022 second_quarter PHA H.R.7900, National Defense Authorization Act for Fiscal Year 2023, Temperature monitoring technology, COVID Rapid Diagnostic Test Kits S.3799, PREVENT Pandemics Act, Rapid Diagnostic Test related issues Monitor Temperature monitoring technology for COVID vaccines, Domestic and International distribution related issues HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2022-07-19T07:22:41-04:00
2827294 TRAVERE THERAPEUTICS fdff7e33-b7f3-4cec-978d-5c58fe0476e7 Q2 TRAVERE THERAPEUTICS 401104190 TRAVERE THERAPEUTICS 2022 second_quarter PHA H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and related Senate legislation. H.R. 19, Lower Costs More Cures Act. Legislative proposals regarding drug pricing, value, and reimbursement in H.R. 5736 Build Back Better Act and related Senate legislation. H.R. 7667, the Food and Drug Amendments of 2022 and related Senate legislation. HOUSE OF REPRESENTATIVES,SENATE   290000 0 0 2022-07-19T07:59:16-04:00
2828116 BURRELL INTERNATIONAL GROUP LLC b96a3ebf-019a-43ef-8599-ee20ee082b47 Q2 BURRELL INTERNATIONAL GROUP LLC 401103483 ACER THERAPEUTICS 2022 second_quarter PHA COVID 19 therapeutics and Medical Countermeasures, Rare Disease and Re-purposed drugs; - FY22 Defense Appropriations for MCM Development HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2022-07-19T10:10:47-04:00
2828302 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 926d02e7-d331-4d0b-934b-023c023c914d Q2 BLUE CROSS AND BLUE SHIELD OF FLORIDA, INC. 6382 BLUE CROSS AND BLUE SHIELD OF FLORIDA INC 2022 second_quarter PHA COVID-19 Testing; Rx Reform; Prescription Drugs; Prescription Drug Reform; OTC COVID-19 Tests; Insulin; Coverage of Testing and Vaccines HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   160000 0 0 2022-07-19T10:28:55-04:00
2828308 KOUNTOUPES DENHAM CARR & REID, LLC 24335d24-ce9c-463a-93bb-765fbef31670 Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2022 second_quarter PHA Issues related to proposals that would address drug shortages and national stockpile issues, including H.R. 2870, the Essential Medicines Strategic Stockpile Act of 2021. Issues related to COVID-19 vaccine distribution. Issues related to pharmacy provider status. Issues related to pharmaceutical supply chain provisions in S. 3799, PREVENT Pandemics Act. Issues related to the budget reconciliation process. Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2022-07-19T10:30:22-04:00
2828335 GUIDEWELL MUTUAL HOLDING CORPORATION 6a3fdeeb-6385-498b-bfa4-5d948204297d Q2 GUIDEWELL MUTUAL HOLDING CORPORATION 401103191 GUIDEWELL MUTUAL HOLDING CORPORATION 2022 second_quarter PHA COVID-19 Testing; Rx Reform; Prescription Drugs; Prescription Drug Reform; OTC COVID-19 Tests; Insulin; Coverage of Testing and Vaccines HR 3 (117th Congress), Elijah E. Cummings Lower Drug Costs Now Act, by Rep. Frank Pallone (D-NJ). Establishes a fair price negotiation program, protect the Medicare program from excessive price increases, and establish an out-of-pocket maximum for Medicare part D enrollees. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office     0 0 2022-07-19T10:33:02-04:00
2828378 UC HEALTH b825d0b4-dbaa-4db9-a841-689e79e4292a Q2 UC HEALTH 401103195 UC HEALTH 2022 second_quarter PHA 340B, Drug Pricing Reform, PBMs HOUSE OF REPRESENTATIVES,SENATE   37500 0 0 2022-07-19T10:36:22-04:00
2828405 KOUNTOUPES DENHAM CARR & REID, LLC f2c485f2-c4c2-43be-9af1-fcf0b6f2f9a1 Q2 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2022 second_quarter PHA General issues related to over-the-counter pharmaceutical supply chain. Issues related to dietary supplements, including in the prescription drug user fee agreement (PDUFA) VII.   50000   0 0 2022-07-19T10:42:37-04:00
2828752 MASSACHUSETTS MEDICAL SOCIETY dc2e9f27-b5f7-40fa-9cf3-40a1a2a8b777 Q2 MASSACHUSETTS MEDICAL SOCIETY 23975 MASSACHUSETTS MEDICAL SOCIETY 2022 second_quarter PHA Prescription Drug Pricing Issues related to prescription drug pricing - no specific bill HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2022-07-19T11:18:36-04:00
2828914 HERITAGE ACTION FOR AMERICA 0020b9ee-c729-487f-97a6-b80261c57889 Q2 HERITAGE ACTION FOR AMERICA 400609853 HERITAGE ACTION FOR AMERICA 2022 second_quarter PHA HR 7667 "Food and Drug Amendments Act," all provisions. HOUSE OF REPRESENTATIVES   110000 0 0 2022-07-19T11:31:15-04:00
2829075 RUBICON ADVISORS, LLC 793123b9-5325-413f-bbbd-7d8a5f3f70af Q2 RUBICON ADVISORS, LLC 315091 DYNAVAX TECHNOLOGIES 2022 second_quarter PHA Prescription Drug User Fee, Biomedical Advance Research and Development Authority (BARDA) HOUSE OF REPRESENTATIVES,SENATE,State, Dept of (DOS) 75000   0 0 2022-07-19T11:43:43-04:00
2829102 RUBICON ADVISORS, LLC c1390bb2-24d0-4414-a3b2-6087314d6461 Q2 RUBICON ADVISORS, LLC 315091 DR. REDDY'S LABORATORIES, LTD 2022 second_quarter PHA Prescription Drug User Fee (PDUFA) re authorization.Generic Drug User Fee Act (GDUFA) re authorization. Border Adjustment Tax(BAT)issues Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 60000   0 0 2022-07-19T11:45:44-04:00
2829111 RUBICON ADVISORS, LLC 19447641-2da9-4fa0-846b-27e2b43495b5 Q2 RUBICON ADVISORS, LLC 315091 CONSCIOUS DISCIPLINE 2022 second_quarter PHA Medicare HOUSE OF REPRESENTATIVES,SENATE 67500   0 0 2022-07-19T11:46:57-04:00
2829130 RUBICON ADVISORS, LLC 598f6eea-2507-4bb4-af66-ef610d52ba05 Q2 RUBICON ADVISORS, LLC 315091 LANNETT COMPANY, INC 2022 second_quarter PHA Medicare and Medicaid, Generic Prescription, COVID-19 Stimulus Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) 50834   0 0 2022-07-19T11:49:14-04:00
2829202 OREGON HEALTH & SCIENCE UNIVERSITY 9095bb9a-c10c-4905-bf18-92d036748bd2 Q2 OREGON HEALTH & SCIENCE UNIVERSITY 30291 OREGON HEALTH & SCIENCE UNIVERSITY 2022 second_quarter PHA Support for the 340B Drug Discount Program for safety net hospitals and enforcing the Health Resources and Services Administration's statute governing the program. HOUSE OF REPRESENTATIVES,SENATE   40000 0 0 2022-07-19T11:54:27-04:00
2829228 RUBICON ADVISORS, LLC f5d58a5b-2269-44e9-bafc-acd875793e27 Q2 RUBICON ADVISORS, LLC 315091 AVET PHARMACEUTICALS 2022 second_quarter PHA GENERIC DRUG PRICING,HOUSE COMMITTEE ON OVERSIGHT,GOVERNMENT REFORM, FOOD AND DRUG ADMINISTRATION AND COVID-19 DRUG SHORTAGES Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES 30000   0 0 2022-07-19T11:57:13-04:00
2829229 RUBICON ADVISORS, LLC b56fa0ba-e58b-4341-b1a5-60efab79a1e4 Q2 RUBICON ADVISORS, LLC 315091 ASCENDIS PHARMA, INC. 2022 second_quarter PHA Food and Drug Administration, Orphan Drugs Food & Drug Administration (FDA) 60000   0 0 2022-07-19T11:58:09-04:00
2829232 RUBICON ADVISORS, LLC da531910-2fea-40a2-81a1-ed03aa996024 Q2 RUBICON ADVISORS, LLC 315091 HYPOPARATHYROIDISM ASSOCIATION 2022 second_quarter PHA Rare disease issues Orphan drugs Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS)     0 0 2022-07-19T11:59:14-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 2488.983ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API